SGT-001

The young biotech firm Solid Biosciences Inc (NASDAQ: SLDB) secured two Buy ratings Tuesday and another Wednesday. The Rating Chardan Capital analyst Gbola Amusa initiated Solid Biosciences with a Buy rating and $40 price target. The Thesis Amusa expects gene therapies to penetrate 26.8...